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Single and coaxial electrospraying was used to prepare Eudragit L100-55
polymer microparticles containing prednisolone as the active pharma-
ceutical ingredient. Different compositions of prednisolone and Eudragit
L100-55 were used to develop five different formulations with different
polymer : drug ratios. The resultant microparticles had a toroidal shape
with a narrow size distribution. Prednisolone was present in an amorphous
physical state, as confirmed by X-ray diffraction analysis. Dissolution studies
were carried out in order to investigate the feasibility of the proposed system
for site-specific release of prednisolone. The release rates were interpreted in
terms of diffusion-controlled release. It was shown that utilization of pH-
responsive Eudragit L100-55 could minimize the release of prednisolone in
the acidic conditions of the stomach, which was followed by rapid release
as the pH of the release medium was adjusted to 6.8 after the first 2 h.
This is especially desirable for the treatment of conditions including
inflammatory bowel disease and colon cancer.1. Introduction
An efficient drug delivery system should meet multiple functional requirements
to serve as an ideal means of delivery of an active pharmaceutical ingredient
(API). These include improved solubility and stability of the drug, reduced
dosage and frequency of administration, reduced adverse side effects, mini-
mum toxicity, and foremost the ability to deliver the required amount of
drug to the target location over a long period of time. Change in the environ-
mental pH is one of the most frequently applied stimuli for the development
of triggers for drug release. The development of a pH-sensitive drug delivery
system is mainly established by adopting polymers that bear weak acid (e.g.
carboxylic acid) or base (e.g. primary and tertiary amines) groups with a pKa
that allows sharp changes in the ionization state at the desired pH. As stated
by Rodrı´guez et al. [1], an increase in the degree of ionization enables dramatic
change in the conformation and also the affinity of the chains, both for the sol-
vent and for the intra-chain interactions, causing either disassembly of the
components or swelling–shrinkage of the covalent network. The sensitivity
to change in pH can be tuned by changing the nature of the co-monomers
that are used to synthesize the polymer.
Eudragit L100-55, a copolymer of methacrylic acid and ethyl acrylate, was
used in this study. Eudragit L100-55 dissolves when the pH is 5.5 [2]. Hence,
it is resistant to gastric fluid and therefore it can bypass the stomach and release
the incorporated API into the small intestine. Eudragit polymers have been
extensively used for development of oral dosage formulations including
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these polymers have also been used for preparation of
microspheres and nanoparticles for controlled drug release
systems in the gastrointestinal (GI) tract [4]. In a study by
Hao et al. [5], Eudragit L100-55 was used as an enteric coating
agent for encapsulation of aspirin in which the drug stability
in the acidic environment of the upper GI tract was preserved
while achieving mild cytotoxicity in vitro. A novel method
to develop pH-responsive microparticles was reported by
Alhnan et al. [6] in which they prepared formulations from
aqueous solutions through spray-drying. They used Eudragit
S and Eudragit L in order to develop gastric-resistant micro-
particles and successfully achieved fast and localized drug
release at the small intestine. Hao et al. [7] used Eudragit
L100-55 to develop enteric nanoparticles incorporating
omeprazole, which is unstable in an acidic environment.
Here, the emulsion diffusion method in conjunction with
ultrasonic solidification was used to prepare the pH-sensitive
drug delivery systems. In another study by Huanbutta et al.
[8] electrohydrodynamic atomization was used to prepare
prednisolone-loaded microparticles using Eudragit S. High
encapsulation efficiency and compatibility of the proposed
system was highlighted by these authors nonetheless no
release study was conducted in order to further examine
the proposed drug delivery system.
Colon-specific drug delivery is particularly advantageous
for treatment of inflammatory bowel disease (IBD), which
includes ulcerative colitis and Crohn’s disease. Furthermore,
oral delivery has been proven to be the most convenient
route of administration of drug to patients [9]. Nonetheless,
the variation in pH that a drug is exposed to, before it reaches
the desired release location, remains an obstacle. Localized
delivery of drugs is a prerequisite for optimum treatment of
these chronic conditions, which require sustainable treatment.
Thus, development of targeted delivery of an API to a specific
region of the colon, where the API is protected from premature
absorption in the upper GI tract, is of great significance. The
variation in pH along the GI tract has been exploited for this
purpose. In a study by Kendall et al. [10], the oil-in-oil emul-
sion technique was used for fabrication of pH-responsive
acrylic microparticles for targeted GI delivery of prednisolone
using Eudragit L55, S and L. It was discovered that Eudragit L
was the most fitting polymer for this purpose, because it
displays minimal drug release under acidic conditions and
achieves optimum drug release when it reaches the pH
threshold of the corresponding polymer carrier.
Prednisolone is among the most frequently prescribed
drug for treatment of IBD. It is a corticosteroid that is
widely used as both an immunosuppressant and an anti-
inflammatory drug to treat a number of inflammatory and
autoimmune conditions. However, because high dosages
are used at frequent predetermined time intervals, it also
induces adverse side effects [11,12]. Furthermore, it has
poor water solubility, a characteristic of class II substances
according to the Biopharmaceutics Classification System
[13]. This is one of the major challenges in the development
of oral formulations and is proven to be a limiting factor in
drug bioavailability, which is directly related to the dissol-
ution rate of the drug. Accordingly, various techniques
including solid dispersion and preparation of liquisolid com-
pacts [14,15] have been used for enhancement of the water
solubility of prednisolone. Nonetheless, recent reports show
that prednisolone-loaded particles have a low encapsulationefficiency [16]. In a study by Bı´lkova´ et al. [17], prednisolone
drug delivery systems with a highly selective release profile
were developed using a-amino-v-methoxypoly(ethylene
glycol) and star a-aminopoly(ethylene glycol). They studied
different approaches for obtaining rate-controlled release
profiles and reported successful development of a drug deliv-
ery system that offers the potential for targeted release of
prednisolone in transplanted liver. In another study by
Bı´lkova´ et al. [18], a drug delivery system with a delayed
release profile of prednisolone was implemented, based on
transient molecular protection of the pH-sensitive linker
with a-cyclodextrin at the molecular level. The prepared
polypseudorotaxane offered a promising oral delivery
system with a pH-sensitive linker which exhibited delayed
acid-catalysed hydrolysis.
Electrospraying has been investigated thoroughly as a
potential technique for pharmaceutical applications [19] and
more specifically for dissolution enhancement of water-inso-
luble drugs by facilitating preparation of the drug delivery
system at reduced size [20], where a higher surface area to
volume ratio greatly favours the rate at which the incorpor-
ated drug is released [21,22]. In a study by Zhang et al.
[23], it was reported that using coaxial electrospraying for
preparation of a griseofulvin formulation using Eudragit
L100 as an encapsulating carrier significantly enhanced the
dissolution and absorption behaviour of the poorly water-sol-
uble drug. This was deemed to be due to the noticeable
reduction in size of the drug carrier, enhanced dispersity
and complete amorphization of the drug. A novel drug deliv-
ery system was developed by Wang et al. [24], who used a
single nozzle emulsion electrospraying technique for co-
encapsulation of multiple model drugs. They demonstrated
that, by taking control of the regional drug loading, the
release pattern could be modulated via careful positioning
of incorporated active ingredients and appropriate selection
of the polymer carrier. Alhnan et al. [25] carried out a study
to examine the effects of microparticle and drug properties,
including the size of the carrier and the drug molecular
weight as well as the acid solubility of the drug, on undesired
drug release in an acidic medium from enteric microparticles.
They examined nine different drugs with variable chemical
properties in combination with Eudragit L and S, and con-
cluded that the molecular weight of the drug is the most
crucial determinant for optimum limitation of drug release
in an acidic environment.
In thiswork, electrosprayingwas exploited fordevelopment
and characterization of prednisolone-loaded microparticles
to prepare oral formulations for site-specific delivery using
Eudragit L100-55 as the pH-responsive polymeric carrier. Five
different formulations were prepared using single and coaxial
electrospraying set-ups, with varying polymer : drug ratios,
with the aim of minimizing the drug release in the acidic
environment and achieving rapid release when the pH is
adjusted to the pH threshold of the polymeric carrier. The
solid state and release profiles of the developed formulations
were studied and quantified.2. Material and methods
2.1. Materials
Prednisolone crystalline powder was acquired from Sigma-Aldrich
(Poole, UK) (MW ¼ 360.44 g mol21). Eudragit L100-55 (MW ¼
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Figure 1. Schematic diagram of the coaxial electrohydrodynamic atomization technique. (Online version in colour.)
Table 1. Formulations and compositions of F1–F5.
formulation core solution shell solution
F1 prednisolone 0.1% w/w in MeOH L100-55 2% w/w in isopropanol
F2 prednisolone 0.2% w/w in MeOH L100-55 1% w/w in isopropanol
F3 prednisolone 0.2% w/w in MeOH L100-55 2% w/w in isopropanol
F4 prednisolone 0.2% w/w and L100-55 1% w/w in MeOH L100-55 2% w/w in isopropanol
F5 single - prednisolone 0.1% w/w and L100-55 1% w/w in isopropanol none
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All other chemicals in this work were of analytical grade and
used as provided.
2.2. Preparation and characterization of solutions
Spraying solutions were prepared by dissolving Eudragit L100-
55 and prednisolone in isopropanol and methanol, respectively,
and stirring using a magnetic stirrer to ensure formation of
homogeneous solutions. All solutions were made under ambient
conditions (room temperature 21+18C and relative humidity of
40–60%). Eudragit solutions of 1.0% w/w and 2.0% w/w were
prepared by dissolving the polymer in isopropanol. Prednisolone
solutions of 0.1% w/w and 0.2% w/w were prepared by dissol-
ving the appropriate amount of drug in methanol. Solutions of
prednisolone 0.2% w/w and Eudragit L100-55 1.0% w/w were
prepared by dissolving the appropriate amount of drug and
polymer in methanol. Prednisolone 0.1% w/w and Eudragit
L100-55 1.0% w/w were dissolved in isopropanol. The compo-
sition details of the prepared solutions are shown in table 1,
where they are denoted as F1–F5. Solutions were fed onto 10 ml
airtight syringes to avoid formation of bubbles during processing.Concentric needles of inner diameter 0.6 mm and 1.52 mm
and outer diameter of 0.9 mm and 2.03 mm, respectively, were
connected to a high-precision voltage power supply (figure 1).
The positive electrode of the high-precision DC voltage
power supply (HCP 35-65000; Fug Elektronik, Rosenheim,
Germany) was connected to a metal needle tip. The ground elec-
trode was connected to a metal collector plate. Experiments were
carried out under ambient conditions. Electrical potential was
applied throughout a fixed distance of 250 mm between the con-
centric needle tip and the collection platform. The flow rate was
kept constant for formulations F1, F2, F3, F4 at 6 ml min21 and
12 ml min21 for the inner and outer solution, respectively. The
flow rate for F5 was set at 12 ml min21. The applied voltage
was varied from 14 kV to 19 kV, in order to establish a stable
cone jet. Different formulations were prepared using single and
coaxial needle configurations, in order to examine the release
profile of prednisolone combined with different polymer
concentrations.
The characteristic properties of the prepared solutions,
including electrical conductivity, surface tension, viscosity and
density, were measured under ambient conditions (table 2). Elec-
trical conductivity was determined using a conductivity probe
Table 2. Properties of the prepared solutions.
solution surface tension (mN m21) viscosity (mPa s) electrical conductivity (mS cm21)
prednisolone 0.1% w/w in MeOH 23.4+ 0.2 0.8+ 0.3 10.0+ 0.1
prednisolone 0.2% w/w in MeOH 24.4+ 0.3 0.8+ 0.3 2.5+ 0.1
prednisolone 0.1% w/w þ L100-55 1% w/w
in isopropanol
25.2+ 0.5 2.5+ 0.5 3.2+ 0.1
prednisolone 0.2% w/w þ L100-55 1% w/w
in MeOH
25.5+ 0.4 0.9+ 0.3 30.6+ 0.4
L100-55 2% w/w in isopropanol 26.2+ 0.3 2.8+ 0.1 5.3+ 0.1
L100-55 1% w/w in isopropanol 25.8+ 0.2 2+ 0.1 3.2+ 0.1
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using a U-tube viscometer (75 ml Cannon-Fenske Routine
Viscometer; Cannon Instruments, USA), and a Kruss tensiometer
(model-K9; Kruss GmbH, Germany) was used to determine the
surface tension. The viscometer, tensiometer and electrical
conductivity probe were calibrated before measurement.
Methanol has a higher electrical conductivity than that of isopro-
panol. Both solvents had nearly the same surface tension with
measured values of 27.0+ 0.2 mN m21 and 26.7+0.2 mN m21
for methanol and isopropanol, respectively. Isopropanol is
slightly more viscous than methanol with measured viscosities
of 1.4+ 0.1 mPa s and 0.7+0.2 mPa s, respectively.
2.3. Characterization of particle size and morphology
2.3.1. Scanning electron microscopy
The morphology of the developed formulations was assessed
using a scanning electron microscope (SEM; XL30 FEG; Philips).
Using ImageJ software, particle size distribution, average
diameter and standard deviation of the particle population
were assessed by measuring the size of 300 particles for each
developed formulation.
2.3.2. X-ray diffraction
X-ray diffraction (XRD) patterns were acquired using a Mini-
Flex600 diffractometer (Rigaku, Tokyo, Japan), with Cu Ka
radiation (l ¼ 1.5418 A˚) at 40 kV and 15 mA. Data were obtained
over the 2u range 5–458 and at a scan speed of 28min21.
2.3.3. Differential scanning calorimetry
Differential scanning calorimetry (DSC) measurements were per-
formed using a TA Instruments Q1000 Differential Scanning
Calorimeter in order to assess the physical state of the drug
within the formulations. Samples of pure drug and polymer
and the various formulations were weighed (3–4 mg) in pierced
aluminium pans and evaluated over the temperature range of
40–2708C at a heating rate of 108C min21.
2.3.4. Fourier transform infrared spectroscopy
A Spectrum 100 spectrometer (PerkinElmer, Massachusetts,
USA) was used to record Fourier transform infrared (FTIR) spec-
tra. The spectrometer was fitted with an attenuated total
reflectance attachment (ATR-FTIR). The samples were scanned
over the range of 4000–650 cm21, with the resolution set at
1 cm21.
2.3.5. Drug encapsulation efficiency
A total of 20 mg of each formulation was dissolved in 20 ml etha-
nol to determine the actual amount of drug encapsulated in the
particles with respect to its theoretical value. This was done inorder to measure the encapsulation efficiency of each formulation.
The following equation was used for the calculations:
encapsulation efficiency (EE%):
actual drug loaded weight
theoretical drug loaded weight
100% :
ð2:1Þ2.3.6. In vitro drug release
A total of 50 mg of particles was placed in an empty capsule. The
capsules were loaded onto enclosed metallic sinkers. The sinkers
were attached to the rotating rods in the dissolution apparatus.
The beakers were filled with buffer solution under 50 r.p.m. con-
tinuous stirring at a set temperature of 37+ 0.58C. In vitro drug
dissolution tests were conducted in 750 ml hydrochloric acid
solution pH 1.2 for the first 2 h. Thereafter, the pH of the dissol-
ution medium was adjusted to 6.8 for the following 6 h. The
release studies were conducted according to the United States
Pharmacopeia standards. At predetermined periodic intervals,
3 ml aliquots were withdrawn from the dissolution medium
and replaced with 3 ml of preheated fresh buffer solution to
ensure a constant volume and maintain sink conditions. The
drug concentrations in the withdrawn aliquots were obtained
using UV spectrometry (6305 spectrophotometer; Jenway, UK).
The detection wavelength was set at 247 nm. Experiments were
conducted in triplicate and results recorded as mean+ s.d.3. Results and discussion
3.1. Morphology
The solution fed into the process, in electrospraying, under-
goes various modes. The establishment of different modes
exhibited is interplay between solution physico-chemical
characteristics and experimental parameters. Experimental
parameters, namely the applied voltage, the set flow rates
and the working distance between the needle exit and the col-
lection platform, are the primary parameters that determine
the window at which a stable cone jet can be formed. In
addition to the operating parameters, the properties of the
liquid, including the electrical conductivity and viscosity,
govern the establishment of the stable cone jet mode [26].
For all formulations, any applied voltage lower or higher
than that of a stipulated range resulted in the formation of
an unstable jet or multiple jets, which would in turn result
in the formation of particles with a large size distribution.
The consistent working distance and set flow rates were
chosen to minimize significant size variation among devel-
oped formulations. This enabled limitation of the potential
factors affecting this variance, which is deemed to be
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Figure 2. Size distribution graphs and scanning electron microscopy images of the particles prepared from formulations F1–F5. (Online version in colour.)
rsif.royalsocietypublishing.org
J.R.Soc.Interface
15:20180491
5
 on September 6, 2018http://rsif.royalsocietypublishing.org/Downloaded from favourable in terms of enabling correct analysis of the release
profiles obtained from each formulation and isolating the
primary factors leading to achievement of the different
release patterns.The particle morphology of the prepared formulations is
demonstrated in figure 2; as can be deduced from the SEM
images, the particles adopted the form of doughnut-shaped
encapsulating matrices. The hypothesis is that the periphery
Table 3. Encapsulation efﬁciency and mean particle size data for the prepared formulations.
formulation mean particle outer diameter (mm) mean particle inner diameter (mm) encapsulation efﬁciency (%)
F1 3.2+ 1.0 0.7+ 0.2 93
F2 3.0+ 0.6 0.5+ 0.1 81
F3 4.2+ 1.0 0.5+ 0.2 83
F4 3.8+ 1.4 0.4+ 0.1 84
F5 1.7+ 0.4 0.6+ 0.2 76
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Figure 3. X-ray diffractograms of (a) prednisolone and Eudragit L100-55 and
(b) the developed formulations (F1–F5). Arbitrary units are indicated by
arb. units (Online version in colour.)
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[27]. Solvent removal from the surface results in an increase in
the concentration of the polymer near the surface; this culmi-
nates in the formation of toroidal structures. Use of high-
molecular-weight Eudragit L100-55 (320 kDa) resulted in lim-
ited mobility of the polymer solution as the drying process
occurred. For this reason, the formation of spherical particles
was prohibited. The formation of toroidal structures was
consistent in all formulations, although the polymer
concentration was kept at the lowest possible value due to
the high viscosity of the prepared solution, while at the
same time enabling production of particles.
In terms of size, F1 and F3 formulations consisted of
the same outer solution, with F3 having a higher drug
concentration in the core needle (table 1). The averageapplied voltage was slightly higher for F1, at 19 kV,
than for F3, 16 kV. Hence, the F1 average particle size was
3.2+1.0 mm as opposed to 4.2+ 1.0 mm for F3, as shown in
table 3; this is consistent with the literature [28]. The outer sol-
ution in F4 also has the same polymer concentration as F1 and
F3, but, in this formulation, the inner solution consisted of
both the drug and polymer, in order to further decrease the
drug release in the first 2 h before it reaches the intestine.
Inclusion of polymer, as well as having relatively lower
applied voltage of 15–18 kV, resulted in a higher average
particle size than that of F1, at 3.8+1.4 mm (figure 2). Also,
when compared with F3, F4 has a lower than average particle
size, where the applied voltage is slightly lower for F3 at 16 kV.
The constituent of the inner solution for F2 and F3 was kept
unchanged; however, the outer solution in F3 had a higher
polymer concentration than that of F2, and the average particle
size was 3.0+ 0.6 mm at an applied voltage of 18–19 kV for
F2, and 4.2+1.0 mm at an applied voltage of 16 kV for F3.
The slightly higher particle size of F3 can be explained by
the higher polymer content, as well as the lower applied vol-
tage. Among all the developed formulations, F5, for which
single needle electrosprayingwas used, had the lowest particle
size at 1.7+ 0.4 mm and applied voltage of 14–19 kV.
Although the polymer : drug ratio for F5 was the same of
that for F2, having no outer shell solutions resulted in a
reduction in particle size.
3.2. Phases
The XRD patterns of the polymer, Eudragit L100-55, and the
drug, prednisolone, and also those of the developed formu-
lations are illustrated in figure 3. Prednisolone exhibited
numerous reflections and sharp peaks at 15.758, 17.648,
21.338, 22.778, 25.278 and 26.318, demonstrating its crystalli-
nity. Eudragit L100-55 displayed the characteristic broad
hump of amorphous materials. As shown in the diffracto-
grams obtained for the developed formulations, the
amorphous nature was most prominent. In all formulations,
the characteristic peak of prednisolone at 2u of 15.78 was
found to be invisible and overlapped with that of Eudragit
L100-55 at 2u of 20.768. As illustrated by the superimposed
X-ray diffractograms of the formulations, the amorphous
state of prednisolone within the formulations can be estab-
lished, confirming that the drug is molecularly dispersed in
Eudragit L100-55.
3.3. Thermal properties
DSC analyses were performed in order to evaluate possible
solid-state interactions between the components and, conse-
quently, to assess the actual drug–excipient compatibility in
all the examined formulations. The thermal curves of pure
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of the developed formulations (F1–F5) are shown in figure 4.
The DSC curve of the pure drug is indicative of its crystal-
line state, displaying a sharp endothermic peak at 2358C. The
thermal profile of Eudragit L100-55 exhibited a broad
endothermic band that ranged between 508C and 1008C,
due to dehydration as evaporation of unbound water took
place. The second endothermic effect was observed at a
higher temperature, and is attributable to the melting of its
crystalline phase. Eudragit L100-55 is a heat-labile polymer
that undergoes thermal degradation at 1508C by decompo-
sition of carboxylic side groups, followed by chain
decomposition at 1808C [29]. The thermal curves of the devel-
oped formulations (F1, F2, F3 and F4) almost corresponded to
those of the pure components, demonstrating the absence of
solid-state interactions and allowing assessment of drug–
polymer compatibility in all the examined formulations. As
shown from the thermograms obtained for F1, F2, F3 and
F4, the melting temperature of prednisolone shifted to a
lower value as the L100-55 has acquired a higher degradation
temperature, and the new Tm is at an intermediate point
between the two. This shift is steepest for F1, where the
polymer : drug ratio is at its highest; this may be due to
random dispersion of prednisolone molecules within the
polymeric carrier and a semi-crystalline structure.3.4. Compositional features
FTIR spectroscopy was used in order to characterize possible
interactions between the drug and the polymer in the solidstate. FTIR spectra of the unprocessed material, the unloaded
and loaded formulations and the physical mixture were
obtained as illustrated in figure 5. The spectrum of predniso-
lone showed characteristic bands of the OH group at 3200–
3500 cm21 (OH involved in intermolecular association). The
characteristic stretching vibrations of C¼O at 1700 cm21
and C¼C at 1660 cm21 appear as very strong bands. The
spectrum of Eudragit L100-55 shows characteristic bands of
methyl and methylene CH stretch vibrations at 3000 cm21
and 2936 cm21, a strong band owing to carbonyl groups at
1723 cm21 (C¼O stretch) and two bands at 1267 cm21 and
1165 cm21 that are due to ester linkages (COC stretches).3.5. Drug release
To investigate prednisolone release profiles from Eudragit
L100-55 developed formulations, in vitro dissolution tests
were conducted on F1–F5 under acidic conditions pH 1.2
for the first 2 h, which replicates the stomach passage transit
time, followed by 6 h at pH 6.8, which mimics intestinal con-
ditions. The drug release profiles are shown in figures 6 and
7. The encapsulation efficiencies obtained for all formulations
are presented in table 3.
Prednisolone release from all formulations is retarded to
different extents during the initial 2 h of release in an acidic
environment, depending on the composition of the formu-
lation. This is due to the insolubility of Eudragit L100-55 at
pH, 5.5. It can be seen from the release graphs that the pre-
dnisolone release during the first 2 h is at its highest for F3 .
F5 . F1 . F2. F4. Although the polymer : drug ratio is kept
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Figure 8. Observed (solid) and fitted (dashed) release profiles for the five
particle formulations (F1–F5) during the first 2 h.
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is higher for F5, where the polymer and drug were fed into
single needle electrospraying, as opposed to F2, where the
drug solution was fed only into the inner needle. Moreover,
the mean particle size corresponding to F5 is lower at 1.7+
0.4 mm than that corresponding to F2 with a mean particle
size of 3.0+0.6 mm. It was also found that the drug encapsu-
lation efficiency was higher for F2 at 81% than for F5 at 76%.
The drug release was at its least for F4, whereby Eudragit
L100-55 was incorporated in both the inner and outer sol-
utions fed into the coaxial electrospraying, where
prednisolone was only in the core solution. The
encapsulation efficiency was at peak value for F1, 93%,
where the polymer concentration with respect to drug was
at its highest.
After the first 2 h, when the pH is at 6.8, F1 shows the fast-
est initial dissolution rate. Prednisolone release exhibits a
more sustained pattern for F4 and F5 when the drug release
reaches a plateau after 3 h. The drug release rate in mg ml21
follows the order F2. F5 . F3. F1. F4. Total drug release
over a longer time span is shown in figure 7. Although
Eudragit L100-55 is soluble at pH. 5.5, the drug dissolution
process did not occur instantly, which shows that further
physical processes take place before the incorporated drug
reaches its maximum release amount in the release
medium. Particles need to absorb water, swell and disentan-
gle prior to complete dissolution of the incorporated drug.
The obtained results show that both the polymer : drug con-
centration ratio and solution compositions using single andcoaxial electrospraying set-ups can affect both encapsulation
efficiency and dissolution rate. It can be concluded that using
polymer in both the core solution and the shell solution can
further prolong the release and yield higher encapsulation
efficiency.
3.6. Modelling the drug release
The micrographs of the particles suggest that the morphology
is more toroidal than spherical, so we have considered the
effect of this on the release rates. Unfortunately, the time-
dependent diffusion equation is not separable in toroidal
coordinates. It is possible [30] to establish a hierarchy of
coupled partial differential equations representing an expan-
sion in powers of r/R, where R is the radius of the toroid and
r is the radius of the tube which forms the toroid. The
first term in the expansion is the same as the result for an
infinite cylinder of radius r, and the lowest-order correction
is proportional to (r/R). To investigate further we have
undertaken numerical calculations of the release rates from
toroids using a finite-element method in the FreeFEMþþ
code [31]. We consider particles in which an active ingredient
is initially uniformly distributed, and diffuses with coefficient
D into a surrounding material in which the concentration
is zero. We found that the rate of release is independent
of the ratio r/R, and is numerically identical to the rate of
release from a cylinder of radius r. Accordingly, we have
fitted the early stage release rates by using the following
expression, which we have found to give a good fit to
well-known exact analytical results [32]:
wðtÞ ¼ tanhð2:415pðDtÞ=rÞ: ð3:1Þ
For comparison, we have also used the expression pre-
viously derived [33] for spheres of radius a,
wðtÞ ¼ tanhð3:345pðDtÞ=aÞ: ð3:2Þ
We note that both expressions can be represented by the
functional form tanh(a
p
t): the interpretation of a in terms
of a diffusion coefficient depends on the particle size and
shape.
The release rate in a less acidic environment is so rapid
that the experimental measurements are not closely
enough spaced to justify detailed numerical fits: neverthe-
less, we have again used the expressions in equations (3.1)
and (3.2) to describe the release after 2 h in order to gain
Table 4. Diffusion coefﬁcients D for the ﬁrst 2 h of release deduced from ﬁtting the experimental results with equations (3.2) and (3.1).
formulation sphere diameter (mm) D/(m2 s21) (sphere) cylinder diameter (mm) D/(m2 s21) (cylinder)
F1 3.2 4.0  10218 1.25 4.7  10218
F2 3.0 2.1  10218 1.25 2.8  10218
F3 4.2 1.6  10217 1.85 2.4  10217
F4 3.8 1.2  10218 1.70 1.8  10218
F5 1.7 1.5  10218 0.55 1.2  10218
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constant in Eudragit in the two environments. We do not
attempt to make any allowance for dimensional changes of
the particles.
Figure 8 compares the best fits to the release rates for the
first 2 h with the experimental results. We note that the fits
are rather poor over the first minutes of the release, suggesting
that a slightly different mechanism is in operation during
these very early stages. If these fits are interpreted in terms
of a diffusion coefficient, the results are as shown in table 4.
It is notable that the dependence of the results on the assumed
geometry is weaker than the dependence on the particle
formulation. The release rate curves clearly show an increase
in rate after the decrease in pH of the surrounding solution.3.7. Clinical perspective
IBD comprises predominantly ulcerative colitis and Crohn’s
disease—two complex, chronic conditions. Crohn’s disease
is characterized by transmural inflammation affecting any-
where along the GI tract, most commonly the terminal
ileum. Ulcerative colitis is described as mucosal inflammation
restricted to the colon, often affecting the distal colon in a
continuous manner. Symptoms can include severe diarrhoea
and abdominal pain, frequently presenting with weight loss
and malaise. Both conditions have the capacity to greatly
affect an individual’s day-to-day life and, in some cases,
pose life-threatening emergencies. The variable nature of
IBD in each patient means we are faced with challenges in
providing effective treatment. The anti-inflammatory effects
of corticosteroids such as prednisolone can induce remission
and prevent acute flares of the disease.
Targeted drug delivery to the bowel is highly desirable
owing to the changing environment along the GI tract. The
steroids taken via the oral route are susceptible to changes in
pH, enzymatic action and prolonged transit times, compro-
mising absorption. Our understanding of the gut physiology
can however be used to our advantage. To tailor the drug dis-
tribution to the section of bowel affected, one must understand
the changes in pH along the GI tract. The stomach tends to be
extremely acidic, the pH then becomes more alkaline moving
along the small intestine, reaching approximately 7.4 at the
distal small intestine. Moving into the colon, the pH drops
at the caecum to approximately 5.7, rising once again to 6.8
at the rectum. The pH can further be influenced by dietary
intake, resident gut flora and disease-induced inflammation.
Having a prednisolone coating that is initially resilient to
acidic pH but then highly responsive to a higher pH allows
for a much more efficient and successful delivery. Tailoring
experiments to exact pH variation is however difficult, butthe work described in this paper furthers this aim
significantly.
Prolonged use of steroids unfortunately comes with sys-
temic side effects including hyperglycaemia, gastric irritation
and osteoporosis. Formulations which are pH responsive are
therefore highly attractive to both the prescriber and the
patient. By optimizing where the drug acts we can reduce
the dose and frequency required, restricting the undesired
effects. Through optimizing the safety and efficacy of predni-
solone, we have the potential to greatly improve patient
compliance and reduce costs of administering excessive quan-
tities of steroids. Prednisolone is implicated in the treatment of
many bowel pathologies, including carcinoma of the bowel,
the prevalence of which is rising rapidly. The carefully con-
structed drug formulations described are able to work in
combination with our gut physiology rather than against it,
which makes a wide range of future applications possible.4. Conclusions
We report successful preparation of a series of five formu-
lations of prednisolone for localized delivery using
electrospraying. These include toroidal microparticles com-
posed of pH-responsive Eudragit L100-55. XRD showed
that prednisolone was in an amorphous state in the formu-
lations. Dissolution studies showed that the proposed drug
delivery system was successful in terms of minimization of
prednisolone release within the first 2 h under the acidic con-
ditions of the stomach at pH 1.2, this was followed by
immediate release after the adjustment of the pH to 6.8.
The slower release in the early stages could be described by
a diffusion process. The developed formulations could offer
localized delivery of prednisolone to the colon, where site-
specific release of the API is anticipated for treatment of
inflammatory bowel syndrome or colon cancer. It was
proved that electrospraying offers a versatile platform for
preparation of targeted release formulations by careful selec-
tion of the polymeric system composition that is highly
adaptable to obtain different modes of release based on the
desirable requirements.
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